Abstract
Bothrojaracin (BJC) is a 27-kD protein from Bothrops jararaca venom that interacts with α-thrombin (K<sub>D</sub> = 0.7 nM) through both anion-binding exosites I and II. Recently, it has been shown that BJC interacts with the exosite I precursor (proexosite I) on human prothrombin (K<sub>D</sub> = 75 nM), forming a 1:1 Ca<sup>2+</sup>-independent noncovalent complex with the zymogen. Complex formation was associated with inhibition of zymogen activation by Oxyuranusscutellatus venom. In addition, BJC strongly decreased the prothrombin activation by factor Xa only in the presence of factor Va. A similar effect was observed in the presence of phospholipids, suggesting that BJC specifically inhibits the interaction of prothrombin with factor Va. It is proposed that BJC has two independent mechanisms for anticoagulation: (1) inhibition of exosite-I-dependent activities on α-thrombin, and (2) inhibition of prothrombin activation through interaction with proexosite I.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
